207940.KS
Samsung Biologics Co.,Ltd. [207940.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
207940.KS Stock Summary
Top 10 Correlated ETFs
207940.KS
Top 10 Correlated Stocks
207940.KS
In the News
207940.KS Financial details
Company Rating
Buy
Market Cap
56227.46B
Income
857.69B
Revenue
3694.59B
Book val./share
138119.15
Cash/share
28890.83
Dividend
-
Dividend %
-
Employees
4.28K
Optionable
No
Shortable
Yes
Earnings
22 Apr 2024
P/E
56.29
Forward P/E
-
PEG
105.82
P/S
14.8
P/B
5.52
P/C
26.93
P/FCF
430.66
Quick Ratio
-
Current Ratio
1.32
Debt / Equity
0.19
LT Debt / Equity
0.04
-
-
EPS (TTM)
12.05K
EPS next Y
-
EPS next Q
-
EPS this Y
5.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
31.76%
Revenue last 5Y
39.41%
Revenue Q/Q
3.82%
EPS Q/Q
20.93%
-
-
-
-
SMA20
-6.08%
SMA50
-3.72%
SMA100
9.46%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
10%
ROC
0.1%
Gross Margin
48%
Oper. Margin
33%
Profit Margin
26%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
668000.0-880000.0
52W High
-11.59%
52W Low
+16.47%
RSI
36.91
Rel Volume
0.58
Avg Volume
74.87K
Volume
43.61K
Perf Week
-3.35%
Perf Month
-2.26%
Perf Quarter
7.61%
Perf Half Y
7.91%
-
-
-
-
Beta
0.511
-
-
Volatility
6797.36%, 22927.54%
Prev Close
-1.52%
Price
778000
Change
-0.26%
207940.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 10.49K | 17.42K | 23.45K | 43.03K | 51.91K | |
| Net income per share | 3.03K | 3.6K | 5.89K | 11.44K | 12.05K | |
| Operating cash flow per share | 151.85 | 3.02K | 6.8K | 13.66K | 23.41K | |
| Free cash flow per share | -2.56K | 800.45 | 500.16 | -805.45 | 7.88K | |
| Cash per share | 10.32K | 12.74K | 20.51K | 45.79K | 28.89K | |
| Book value per share | 65.12K | 68.77K | 74.64K | 128.82K | 138.12K | |
| Tangible book value per share | 64.79K | 68.43K | 74.16K | 43.34K | 56.18K | |
| Share holders equity per share | 65.12K | 68.77K | 74.64K | 128.82K | 138.12K | |
| Interest debt per share | 10.16K | 11.98K | 19.55K | 36.96K | 27.97K | |
| Market cap | 28953.57B | 55232.45B | 60381.24B | 57680.59B | 56156.29B | |
| Enterprise value | 29482.18B | 55988.51B | 61626.58B | 59303.8B | 57697.68B | |
| P/E ratio | 142.7 | 229.2 | 153.41 | 72.28 | 65.47 | |
| Price to sales ratio | 41.27 | 47.42 | 38.51 | 19.22 | 15.2 | |
| POCF ratio | 2.85K | 273.31 | 132.82 | 60.52 | 33.7 | |
| PFCF ratio | -169.28 | 1.03K | 1.81K | -1.03K | 100.12 | |
| P/B Ratio | 6.65 | 12.01 | 12.1 | 6.42 | 5.71 | |
| PTB ratio | 6.65 | 12.01 | 12.1 | 6.42 | 5.71 | |
| EV to sales | 42.02 | 48.07 | 39.3 | 19.76 | 15.62 | |
| Enterprise value over EBITDA | 94.04 | 129.85 | 83.2 | 43.19 | 34.06 | |
| EV to operating cash flow | 2.9K | 277.05 | 135.56 | 62.23 | 34.63 | |
| EV to free cash flow | -172.37 | 1.05K | 1.84K | -1.06K | 102.87 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | -0.01 | 0 | 0 | 0 | 0.01 | |
| Debt to equity | 0.15 | 0.17 | 0.26 | 0.28 | 0.19 | |
| Debt to assets | 0.11 | 0.12 | 0.16 | 0.15 | 0.12 | |
| Net debt to EBITDA | 1.69 | 1.75 | 1.68 | 1.18 | 0.91 | |
| Current ratio | 1.96 | 2.97 | 2.55 | 1.54 | 1.33 | |
| Interest coverage | 7.05 | 18.2 | 36.53 | 15.35 | 13.65 | |
| Income quality | 0.05 | 0.84 | 1.16 | 1.19 | 1.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.02 | 0.04 | 0.04 | |
| Research and developement to revenue | 0.07 | 0 | 0.05 | 0.02 | 0.02 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.36 | 0.36 | |
| Capex to operating cash flow | -17.85 | -0.74 | -0.93 | -1.06 | -0.66 | |
| Capex to revenue | -0.26 | -0.13 | -0.27 | -0.34 | -0.3 | |
| Capex to depreciation | -1.36 | -1.03 | -2.6 | -3.27 | -2.26 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 66.68K | 74.68K | 99.43K | 182.11K | 193.52K | |
| ROIC | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | |
| Return on tangible assets | 0.03 | 0.04 | 0.05 | 0.08 | 0.08 | |
| Graham Net | -7.19K | -6.89K | -11.54K | -36.56K | -31.2K | |
| Working capital | 665.76B | 1162.05B | 1715.88B | 2276.12B | 1364.13B | |
| Tangible asset value | 4332.63B | 4575.44B | 4958.93B | 3023.17B | 3998.4B | |
| Net current asset value | -200.91B | -74.07B | -155.73B | 1139.92B | -693.72B | |
| Invested capital | 0.15 | 0.17 | 0.26 | 0.28 | 0.19 | |
| Average receivables | 180.3B | 233.6B | 346.1B | 663.58B | 856.32B | |
| Average payables | 6.73B | 33.64B | 43.62B | 45.93B | 133.95B | |
| Average inventory | 377.42B | 549.22B | 829.42B | 1694.34B | 2508.59B | |
| Days sales outstanding | 111.26 | 79.39 | 102.16 | 108.03 | 81.44 | |
| Days payables outstanding | 8.8 | 26.81 | 13.99 | 14.2 | 40.18 | |
| Days of inventory on hand | 324.09 | 314.91 | 439.3 | 565.73 | 509.61 | |
| Receivables turnover | 3.28 | 4.6 | 3.57 | 3.38 | 4.48 | |
| Payables turnover | 41.46 | 13.62 | 26.09 | 25.71 | 9.08 | |
| Inventory turnover | 1.13 | 1.16 | 0.83 | 0.65 | 0.72 | |
| ROE | 0.05 | 0.05 | 0.08 | 0.09 | 0.09 | |
| Capex per share | -2.71K | -2.22K | -6.3K | -14.47K | -15.53K |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 13.57K | 10.13K | 12.17K | 14.53K | 15.08K | |
| Net income per share | 5.2K | 1.99K | 2.6K | 3.38K | 4.08K | |
| Operating cash flow per share | 4.34K | 4.45K | 3.16K | 4.09K | 11.7K | |
| Free cash flow per share | 897.6 | -2.26K | 785.87 | 1.85K | 7.5K | |
| Cash per share | 44.87K | 41.66K | 26.24K | 25.53K | 28.89K | |
| Book value per share | 126.23K | 128.23K | 130.82K | 134.12K | 138.12K | |
| Tangible book value per share | 42.48K | 44.87K | 47.81K | 51.82K | 56.18K | |
| Share holders equity per share | 126.23K | 128.23K | 130.82K | 134.12K | 138.12K | |
| Interest debt per share | 35.67K | 34.71K | 33.55K | 31.15K | 27.1K | |
| Market cap | 58860.9B | 56085.11B | 52953.46B | 48469.49B | 56156.29B | |
| Enterprise value | 60484.11B | 57011.33B | 54787.42B | 50385.95B | 57697.68B | |
| P/E ratio | 39.78 | 98.91 | 71.6 | 50.41 | 48.3 | |
| Price to sales ratio | 60.96 | 77.8 | 61.13 | 46.88 | 52.31 | |
| POCF ratio | 190.39 | 177.08 | 235.11 | 166.33 | 67.43 | |
| PFCF ratio | 921.35 | -348.59 | 946.72 | 367.14 | 105.19 | |
| P/B Ratio | 6.55 | 6.15 | 5.69 | 5.08 | 5.71 | |
| PTB ratio | 6.55 | 6.15 | 5.69 | 5.08 | 5.71 | |
| EV to sales | 62.64 | 79.08 | 63.25 | 48.73 | 53.75 | |
| Enterprise value over EBITDA | 115.29 | 178.29 | 128.26 | 100.41 | 112.09 | |
| EV to operating cash flow | 195.64 | 180 | 243.25 | 172.9 | 69.28 | |
| EV to free cash flow | 946.75 | -354.34 | 979.51 | 381.66 | 108.08 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0.01 | |
| Debt to equity | 0.28 | 0.27 | 0.25 | 0.23 | 0.19 | |
| Debt to assets | 0.15 | 0.15 | 0.15 | 0.14 | 0.12 | |
| Net debt to EBITDA | 3.09 | 2.9 | 4.29 | 3.82 | 2.99 | |
| Current ratio | 1.54 | 1.57 | 1.45 | 1.32 | 1.33 | |
| Interest coverage | 17.58 | 8.83 | 13.5 | 14.72 | 17.97 | |
| Income quality | 0.84 | 2.23 | 1.22 | 1.21 | 2.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.05 | 0.2 | 0.18 | 0.02 | |
| Research and developement to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.36 | 0.36 | 0.38 | 0.37 | 0.36 | |
| Capex to operating cash flow | -0.79 | -1.51 | -0.75 | -0.55 | -0.36 | |
| Capex to revenue | -0.25 | -0.66 | -0.2 | -0.15 | -0.28 | |
| Capex to depreciation | -2.65 | -4.74 | -1.56 | -1.15 | -2.11 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 121.5K | 75.8K | 87.44K | 100.95K | 112.66K | |
| ROIC | 0.03 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Return on tangible assets | 0.03 | 0.01 | 0.02 | 0.02 | 0.03 | |
| Graham Net | -35.83K | -35.66K | -37.09K | -34.5K | -31.2K | |
| Working capital | 2276.12B | 2229.29B | 1631.28B | 1318.81B | 1364.13B | |
| Tangible asset value | 3023.17B | 3193.3B | 3402.83B | 3688.5B | 3998.4B | |
| Net current asset value | 1139.92B | 1141.12B | 1168.69B | -915.22B | -693.72B | |
| Invested capital | 0.28 | 0.27 | 0.25 | 0.23 | 0.19 | |
| Average receivables | 842.89B | 799.72B | 767.71B | 941.05B | 941.08B | |
| Average payables | 77.69B | 97.34B | 151.28B | 165.98B | 186.38B | |
| Average inventory | 2382.62B | 2406.9B | 2483.93B | 2540.56B | 2596.3B | |
| Days sales outstanding | 82.8 | 88.78 | 85.65 | 92.07 | 69.11 | |
| Days payables outstanding | 10.7 | 32.13 | 34.33 | 27.82 | 34.57 | |
| Days of inventory on hand | 426.6 | 579.88 | 518.61 | 431.47 | 438.41 | |
| Receivables turnover | 1.09 | 1.01 | 1.05 | 0.98 | 1.3 | |
| Payables turnover | 8.41 | 2.8 | 2.62 | 3.24 | 2.6 | |
| Inventory turnover | 0.21 | 0.16 | 0.17 | 0.21 | 0.21 | |
| ROE | 0.04 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Capex per share | -3.45K | -6.71K | -2.38K | -2.24K | -4.2K |
207940.KS Frequently Asked Questions
What is Samsung Biologics Co.,Ltd. stock symbol ?
Samsung Biologics Co.,Ltd. is a KR stock and trading under the symbol 207940.KS
What is Samsung Biologics Co.,Ltd. stock quote today ?
Samsung Biologics Co.,Ltd. stock price is $778000 today.
Is Samsung Biologics Co.,Ltd. stock public?
Yes, Samsung Biologics Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 74.87K
- Market Capitalization 56227.46B
- Employee 4.28K
- CEO Mr. John Chongbo Rim
- Headquarters Incheon,KR
- IPO Date 2016-11-11
-
Website
https://samsungbiologics.com 
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
